We are delivering transformational medicines through the understanding of protein-ligand interactions.
New Generation of Menin Inhibitors
Most Acute Myeloid Leukemia (AML) therapies try to kill leukemic cells. But what if you could reprogram them instead, preventing the interaction that keeps them cancerous? That’s the promise of menin inhibitors.
CHARM is taking this one step further with its next generation best-in-class menin inhibitor designed to address resistance observed with first generation menin approaches and deliver a durable treatment to patients.
Our Approach
Founded by leaders with a track record in AI and drug discovery, the CHARM team is advancing its next generation menin inhibitor into the clinic, to transform patient outcomes for AML.
CHARM has designed structurally optimised inhibitors that are highly potent and bind precisely within the KMT2A interface on menin.
About
